Squarepoint Ops LLC Takes Position in FibroGen, Inc. (NASDAQ:FGEN)

Squarepoint Ops LLC purchased a new stake in shares of FibroGen, Inc. (NASDAQ:FGEN) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 162,914 shares of the biopharmaceutical company’s stock, valued at approximately $145,000.

Several other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of FibroGen in the first quarter worth $131,000. Acadian Asset Management LLC grew its stake in shares of FibroGen by 1.4% in the first quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock worth $5,883,000 after acquiring an additional 34,937 shares in the last quarter. Accel Wealth Management acquired a new position in shares of FibroGen in the first quarter worth $103,000. Point72 DIFC Ltd grew its stake in shares of FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 45,990 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of FibroGen in the second quarter worth $424,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen Trading Up 6.0 %

Shares of FGEN stock opened at $0.36 on Monday. The firm has a fifty day moving average price of $0.39 and a 200 day moving average price of $0.91. The company has a market cap of $35.54 million, a P/E ratio of -0.15 and a beta of 0.70. FibroGen, Inc. has a 12 month low of $0.30 and a 12 month high of $2.93.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.09. The company had revenue of $50.64 million during the quarter, compared to analyst estimates of $33.00 million. During the same quarter in the prior year, the company earned ($0.65) EPS. On average, equities analysts forecast that FibroGen, Inc. will post -0.91 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of FibroGen in a research note on Sunday. They set a “hold” rating for the company.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.